Sona Nanotech, Inc. engages in the development of multiple proprietary methods for the manufacture of various types of gold nanoparticles in medical applications. The company is headquartered in Halifax, Nova Scotia. The company went IPO on 2018-10-04. The firm has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). The company is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The firm is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.